Unidade Local de Saúde de Coimbra

Running trials

• Not yet recruiting

  A study to compare heart failure medicines in one combined pill with usual care.

  2026-526510-90-00· Phase 3· Institut De Recherches Internationales Servier IRIS· Source

• Not yet recruiting

  Validation Of anatomY-specific Aortic Valve Implantation Guided by Software Using EncantoR

  NCT07696182· Abbott Medical Devices· Source

• Recruiting

  Home Monitoring in eAMD Treatment

  NCT07340372· Association for Innovation and Biomedical Research on Light and Image· Source

• Recruiting

  Primary Palliative Care - a Feasibility Cluster Trial

  NCT07737899· University of Coimbra· Source

• Recruiting

  A Phase 3 Study Comparing Ramantamig plus Daratumumab Versus DVRd or DRd in Participants With NDMM for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

  2026-526654-14-01· Phase 3· Janssen Cilag International· Source

• Recruiting

  A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum

  NCT07811193· Phase 2· Vividion Therapeutics, Inc.· Source

• Not yet recruiting

  A study that compares Depigoid Olea (a medication to treat olive pollen allergies) and placebo in patients who have a runny nose and pink and itchy eyes due to olive pollen allergy.

  2026-525840-13-00· Phase 3· LETI Pharma S.L.U.· Source

• Not yet recruiting

  Sociocognitive Intervention and Rehabilitation Program in Multiple Sclerosis

  NCT07734675· Sonia Batista· Source

• Not yet recruiting

  Study of a DPP 4 inhibitor and an SGLT2 inhibitor used together compared with each treatment alone in adults with type 2 diabetes treated with metformin.

  2025-524606-15-00· Phase 3· Tecnimede-Sociedade Tecnico-Medicinal S.A.· Source

• Recruiting

  Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation

  NCT07626411· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

  NCT07711418· Phase 3· Nektar Therapeutics· Source

• Not yet recruiting

  Evaluation of a Modified Bowel Preparation Regimen in Cirrhotic Patients Undergoing Colonoscopy

  NCT07668778· Phase 3· Hospital do Divino Espírito Santo de Ponta Delgada· Source

• Recruiting

  A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer

  NCT07673887· Phase 3· Astellas Pharma Global Development, Inc.· Source

• Recruiting

  A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

  NCT07497087· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS

  NCT07665437· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis

  NCT07516951· Phase 2· Chiesi Farmaceutici S.p.A.· Source

• Recruiting

  Pridopidine Phase 3 Study in Huntington's Disease

  NCT07609108· Phase 3· Prilenia· Source

• Recruiting

  A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)

  NCT07647510· Phase 3· Dianthus Therapeutics· Source

• Recruiting

  A clinical trial of EYE201/MK-8748 in people with macular degeneration (MK-8748-003)

  2025-524894-17-00· Phase 2/3· Eyebiotech Limited· Source

• Recruiting

  A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction

  NCT07192952· Phase 3· Bayer· Source

• Recruiting

  A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD

  NCT07285655· Phase 3· Liquidia Technologies, Inc.· Source

• Recruiting

  DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

  NCT07472517· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable

  NCT07430956· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

  NCT07326709· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis

  NCT07286058· Phase 3· Takeda· Source

• Recruiting

  A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)

  NCT07282574· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  Specific Immunotherapy With Mannan-Conjugated Allergoids for HDM-Allergic Rhinitis/Rhinoconjunctivitis. MM09-SIT-063.

  NCT07904052· Phase 3· Inmunotek S.L.· Source

• Recruiting

  Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis

  NCT07325292· Phase 3· Sanofi· Source

• Recruiting

  PERFECT - Portuguese Evolut Registry Studying the Outcomes of Medtronic Evolut™ FX+ TAVI System by Evaluating an Optimal Care Pathway for TAVI

  NCT07343674· Portuguese Association of Interventional Cardiology· Source

• Recruiting

  Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis

  NCT07284459· Phase 2· Contineum Therapeutics· Source

• Recruiting

  A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant

  NCT06932562· Phase 3· European Myeloma Network B.V.· Source

• Active, not recruiting

  A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)

  NCT07107945· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration (4FRONT-2)

  2025-521349-25-00· Phase 3· 4d Molecular Therapeutics Inc.· Source

• Recruiting

  A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)

  NCT07276724· Phase 3· Generate Biomedicines· Source

• Recruiting

  A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

  NCT06937229· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

  NCT07211958· Phase 3· Syndax Pharmaceuticals· Source

• Recruiting

  A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction

  NCT07188805· Phase 3· Bayer· Source

• Recruiting

  Phase III clinical trial to evaluate the efficacy and safety of specific immunotherapy with mannanconjugated allergoids for the treatment of rhinitis/rhinoconjunctivitis in patients allergic to house dust mites.

  2023-508547-51-00· Phase 3· Inmunotek S.L.· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo

  NCT06804811· Phase 3· Incyte Corporation· Source

• Recruiting

  Phase 2 Study of ADX-038 in Participants With Geographic Atrophy

  NCT06990269· Phase 2· ADARx Pharmaceuticals, Inc.· Source

• Recruiting

  Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

  NCT07007065· Phase 3· AbbVie· Source

• Recruiting

  Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

  NCT06659445· Phase 2· ONL Therapeutics· Source

• Recruiting

  A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)

  NCT06405087· Phase 3· Takeda· Source

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)

  2024-516652-18-00· Phase 3· Amgen Inc.· Source

• Recruiting

  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)

  2024-516654-22-00· Phase 3· Amgen Inc.· Source

• Recruiting

  A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS)

  NCT07161258· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting

  NCT07022483· Phase 3· Daiichi Sankyo· Source

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  NCT07037433· Phase 3· Amgen· Source

• Recruiting

  Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

  NCT06757634· Phase 3· Celcuity Inc· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Boehringer Ingelheim· Source

Showing 50 of 133.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer8 recruiting
• Heart failure7 recruiting
• Multiple sclerosis7 recruiting
• Childhood cancers5 recruiting
• Crohn's disease5 recruiting
• Macular degeneration5 recruiting
• Stroke5 recruiting
• Aortic stenosis4 recruiting
• Asthma4 recruiting
• Multiple myeloma4 recruiting
• Acute myeloid leukaemia3 recruiting
• Alzheimer disease3 recruiting
• Chronic kidney disease3 recruiting
• Colorectal cancer3 recruiting
• Migraine3 recruiting
• Ulcerative colitis3 recruiting
• Acute lymphoblastic leukaemia2 recruiting
• Atrial fibrillation2 recruiting
• COPD2 recruiting
• High blood pressure2 recruiting
• Huntington's disease2 recruiting
• Idiopathic pulmonary fibrosis2 recruiting
• Primary biliary cholangitis2 recruiting
• Type 2 diabetes2 recruiting
• Atopic dermatitis (eczema)1 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
• Coronary artery disease1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Endometrial cancer1 recruiting
• Epilepsy1 recruiting
• Follicular lymphoma1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Hidradenitis suppurativa1 recruiting
• IgA nephropathy1 recruiting
• Liver and biliary tract cancer1 recruiting
• Liver cirrhosis1 recruiting
• Metastatic breast cancer1 recruiting
• Myasthenia gravis1 recruiting
• Obesity1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting

Closed trials

• Recruiting

  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

  NCT07037459· Phase 3· Amgen· Source

• Completed

  A Study of the Efficacy and Safety of Efgartigimod in Patients with Primary Sjögren's Syndrome (pSjD) (UNITY)

  NCT06684847· Phase 3· Argenx· Source

• Completed

  Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo® in combination with Yervoy®

  NCT06587451· Phase 3· H e x a l AG· Source

• Active, not recruiting

  Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

  NCT06635824· Phase 3· Genmab· Source

• Completed

  Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures – SHINE

  NCT06425159· Phase 2/3· Biohaven Therapeutics Ltd.· Source

• Active, not recruiting

  A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis

  NCT06470048· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease

  NCT06522997· Phase 2· Bayer· Source

• Active, not recruiting

  A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work

  NCT06290128· Phase 3· Sanofi· Source

• Completed

  Phase 1b Study to Assess the Safety, Tolerability and Pharmacodynamics of PBFT02 in Adult Participants with Frontotemporal Dementia (FTD) and GRN or C9orf72 Mutations

  NCT04747431· Phase 1/2· Passage Bio Inc.· Source

• Completed

  A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

  NCT06077864· Phase 3· Boehringer Ingelheim· Source

• Completed

  A Phase 3, Double-blind Maintenance Study Assessing Rocatinlimab in Moderate-to-severe AD (ROCKET-ASCEND)

  NCT05882877· Phase 3· Amgen Inc.· Source

• Recruiting

  An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.

  NCT05907057· Phase 3· Servier Affaires Médicales· Source

• Recruiting

  Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

  NCT05714085· Phase 2/3· Merck Sharp & Dohme LLC· Source

• Completed

  Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial – Follow Up Long Term Extension (IMPAHCT-FUL)

  NCT05557942· Phase 3· Aerovate Therapeutics Inc.· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Open-label Study to Evaluate the Efficacy, Safety, Tolerability of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis

  NCT04781543· Phase 2· Horizon Therapeutics Ireland Designated Activity Company· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Completed

  A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RO7303509 in Participants With Systemic Sclerosis

  NCT05462522· Phase 1· Genentech, Inc.· Source

• Completed

  A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body

  NCT05568095· Phase 3· Arcus Biosciences, Inc.· Source

• Completed

  A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05321069· Phase 3· Boehringer Ingelheim· Source

• Terminated

  Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

  NCT05268289· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  A Phase 3 Study of Sotatercept in Newly Diagnosed Intermediate- and High-risk Pulmonary Arterial Hypertension (PAH) Patients.

  NCT04811092· Phase 3· Acceleron Pharma Inc.· Source

• Active, not recruiting

  A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria

  NCT05196035· Phase 3· Bayer· Source

• Completed

  Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

  NCT05052801· Phase 3· Amgen· Source

• Completed

  A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors

  NCT05053139· Phase 3· Novo Nordisk A/S· Source

• Completed

  ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

  NCT05021835· Phase 3· Novo Nordisk A/S· Source

• Completed

  Safety and Performance of INVICTA Ventricular DF4 LEADS With Active Fixation-(APOLLO)

  NCT04590144· MicroPort CRM· Source

• Completed

  Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

  NCT04408755· Phase 3· Otsuka Pharmaceutical Development & Commercialization Inc.· Source

• Completed

  Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)

  NCT04751487· Phase 3· Sanofi· Source

• Completed

  A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

  NCT04718389· Phase 3· GlaxoSmithKline· Source

• Active, not recruiting

  A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder

  NCT04658862· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%

  NCT04435626· Phase 3· Bayer· Source

• Completed

  A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)

  NCT04374136· Phase 3· Alector LLC· Source

• Active, not recruiting

  An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis

  NCT03950232· Phase 3· Pfizer· Source

• Active, not recruiting

  Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine

  NCT03836040· Phase 3· Amgen· Source

• Completed

  A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

  NCT03626688· Phase 3· United Therapeutics· Source

• Completed

  A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)

  NCT02932410· Phase 3· Actelion· Source

• Completed

  Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis

  NCT03232073· Phase 3· Actelion· Source

• Completed

  Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)

  NCT02504372· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

  NCT02486718· Phase 3· Hoffmann-La Roche· Source

• Completed

  An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)

  NCT01853826· Phase 3· Boehringer Ingelheim· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Frontotemporal dementia18 works · 2 trials
• Retinitis pigmentosa5 works · 0 trials